KR20120099751A - 줄기 세포 자극용 약학 조성물 - Google Patents

줄기 세포 자극용 약학 조성물 Download PDF

Info

Publication number
KR20120099751A
KR20120099751A KR1020127017238A KR20127017238A KR20120099751A KR 20120099751 A KR20120099751 A KR 20120099751A KR 1020127017238 A KR1020127017238 A KR 1020127017238A KR 20127017238 A KR20127017238 A KR 20127017238A KR 20120099751 A KR20120099751 A KR 20120099751A
Authority
KR
South Korea
Prior art keywords
composition
pharmaceutical composition
fgf
pharmaceutical
factor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020127017238A
Other languages
English (en)
Korean (ko)
Inventor
롤랜드 고든-베레스포드
빈씨엔느 가우신
장-피에르 라떼르 드와니사
크리스티앙 홈시
Original Assignee
카디오3 바이오사이언시즈, 소씨에떼 아노님
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 카디오3 바이오사이언시즈, 소씨에떼 아노님 filed Critical 카디오3 바이오사이언시즈, 소씨에떼 아노님
Publication of KR20120099751A publication Critical patent/KR20120099751A/ko
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/529—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1825—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1833—Hepatocyte growth factor; Scatter factor; Tumor cytotoxic factor II
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1841—Transforming growth factor [TGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1875—Bone morphogenic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020127017238A 2009-12-02 2010-12-02 줄기 세포 자극용 약학 조성물 Withdrawn KR20120099751A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EPPCT/EP2009/066251 2009-12-02
EP2009066251 2009-12-02

Publications (1)

Publication Number Publication Date
KR20120099751A true KR20120099751A (ko) 2012-09-11

Family

ID=42316097

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020127017238A Withdrawn KR20120099751A (ko) 2009-12-02 2010-12-02 줄기 세포 자극용 약학 조성물

Country Status (12)

Country Link
JP (1) JP2013512877A (enExample)
KR (1) KR20120099751A (enExample)
CN (1) CN102711798A (enExample)
AU (1) AU2010326633A1 (enExample)
BR (1) BR112012013164A2 (enExample)
CA (1) CA2781493A1 (enExample)
IL (1) IL219901A0 (enExample)
MX (1) MX2012005976A (enExample)
NZ (1) NZ599930A (enExample)
RU (1) RU2012120834A (enExample)
TW (1) TW201141510A (enExample)
WO (1) WO2011067317A1 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20200041138A (ko) 2018-10-11 2020-04-21 강원대학교산학협력단 인간 전분화능 줄기세포로부터 조혈모세포 및 대식세포 분화 증진 방법
WO2024177208A1 (ko) * 2023-02-23 2024-08-29 서울대학교산학협력단 배외내배엽 줄기세포의 배양용 배지 조성물

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101836029B1 (ko) * 2014-07-07 2018-03-08 메디포스트(주) 자극된 줄기세포 배양액의 발모 촉진능 및 이의 용도
CN105079791A (zh) * 2015-09-18 2015-11-25 郑榆坤 一种刺激体内内源干细胞的组合物及其应用
RU2634576C1 (ru) * 2016-10-24 2017-10-31 Федеральное государственное бюджетное научное учреждение "Томский национальный исследовательский медицинский центр Российской академии наук" (Томский НИМЦ) Способ стимуляции регенерации тканей
CN107050428B (zh) * 2017-03-23 2020-05-05 温州医科大学 Fgf20药物及其对脑创伤的治疗应用
CN107648592B (zh) * 2017-11-13 2021-05-14 深圳市喆邦生物工程有限公司 趋化因子ccl4作为制备治疗骨折药物的应用
RU2686718C1 (ru) * 2018-03-12 2019-04-30 Федеральное государственное бюджетное научное учреждение "Томский национальный исследовательский медицинский центр Российской академии наук" (Томский НИМЦ) Средство, стимулирующее функции мезенхимальных клеток-предшественников in vitro
CN111195350A (zh) * 2020-01-15 2020-05-26 重庆大学 IGF1和IGF1Ec24联合在制备促进组织修复与再生的药物中的应用
US20240058389A1 (en) * 2020-03-17 2024-02-22 Hierabio Inc. Composition for preventing or treating ischemic diseases, comprising cardiac stem cells
CN111621525B (zh) * 2020-06-18 2021-04-23 中赛干细胞基因工程有限公司 Stx1b基因在促进人脂肪间充质干细胞生长和分化中的用途
CN116836920B (zh) * 2023-08-21 2024-05-24 广东横琴粤澳深度合作区齐美国际干细胞医院有限公司 一种无血清培养基及其制备间充质干细胞的方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2532909T3 (es) * 2004-07-30 2015-04-01 Mayo Foundation For Medical Education And Research Tratamiento de tejido cardiovascular
AU2006208241B2 (en) * 2005-01-25 2011-08-04 Five Prime Therapeutics, Inc. Compositions and methods for treating cardiac conditions
US9765298B2 (en) * 2006-07-24 2017-09-19 Mayo Foundation For Medical Education And Research Methods and materials for providing cardiac cells
US8481075B2 (en) * 2007-12-13 2013-07-09 Beijing Shengyiyao Science & Technology Development Co. Ltd. Preparation and application of biodegradable-material-made microsphere vascular embolus containing liposome-encapsulated cytokines

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20200041138A (ko) 2018-10-11 2020-04-21 강원대학교산학협력단 인간 전분화능 줄기세포로부터 조혈모세포 및 대식세포 분화 증진 방법
WO2024177208A1 (ko) * 2023-02-23 2024-08-29 서울대학교산학협력단 배외내배엽 줄기세포의 배양용 배지 조성물

Also Published As

Publication number Publication date
AU2010326633A1 (en) 2012-05-31
IL219901A0 (en) 2012-07-31
TW201141510A (en) 2011-12-01
MX2012005976A (es) 2012-06-25
CA2781493A1 (en) 2011-06-09
WO2011067317A1 (en) 2011-06-09
JP2013512877A (ja) 2013-04-18
CN102711798A (zh) 2012-10-03
BR112012013164A2 (pt) 2016-03-01
NZ599930A (en) 2014-04-30
RU2012120834A (ru) 2014-01-20

Similar Documents

Publication Publication Date Title
EP2506867B1 (en) Pharmaceutical compositions for the stimulation of stem cells.
KR20120099751A (ko) 줄기 세포 자극용 약학 조성물
Shyu et al. Homing genes, cell therapy and stroke
RU2311921C2 (ru) Лекарственные средства для лечения ишемических заболеваний
JP2013512877A5 (enExample)
AU673659B2 (en) Medicament for promoting growth of mammalian nerve
EP2219656A2 (en) Methods for the repair and/or regeneration of damaged myocardium using variants of hepatocyte growth factor
Zisa et al. Intramuscular VEGF repairs the failing heart: role of host-derived growth factors and mobilization of progenitor cells
JP2021181488A (ja) 組織治癒剤
Cho et al. Enhancement of angiogenic efficacy of human cord blood cell transplantation
Jeon et al. Synergistic effect of sustained delivery of basic fibroblast growth factor and bone marrow mononuclear cell transplantation on angiogenesis in mouse ischemic limbs
JP5205668B2 (ja) 可動化活性を有する調製物
US20230285507A1 (en) Compositions and methods for cardiac tissue repair
US8119397B2 (en) Therapeutic agents and therapeutic methods for treating injured tissue
Waksman et al. Bone marrow and bone marrow derived mononuclear stem cells therapy for the chronically ischemic myocardium
AU2001258322A1 (en) Formulation having mobilising activity
KR101144687B1 (ko) Ｇ－ｃｓｆ 를 함유하는 선유아세포 동원제 및 창상 치료제
US11564943B2 (en) Platelet concentrate for increase of cell regeneration and cell growth
JPH101439A (ja) 神経変性疾患治療剤
KR20060008870A (ko) Ｇ-ｃｓｆ와 혈관 신생 작용을 갖는 인자의 병용
US20200009226A1 (en) Compositions and Methods for Treating Stroke
JP4790195B2 (ja) 組織再生剤
Beohar et al. Cytokine treatment for cardioprotection and cardiac regeneration
Ramesh et al. Prospective Implications of Autologous Platelet-Rich Plasma in Tissue Engineering and Organ Rejuvenation
Levy et al. Basic principles of angiogenesis for the interventional cardiologist

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20120702

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PC1203 Withdrawal of no request for examination
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid